Cytokinetics, Incorporated
CYTK
$38.34
$0.290.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.77M | 1.58M | 16.93M | 463.00K | 249.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.77M | 1.58M | 16.93M | 463.00K | 249.00K |
| Cost of Revenue | 112.55M | 99.84M | 93.63M | 84.61M | 79.60M |
| Gross Profit | -45.79M | -98.26M | -76.70M | -84.15M | -79.35M |
| SG&A Expenses | 65.72M | 57.37M | 62.34M | 56.65M | 50.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 178.28M | 157.21M | 155.97M | 141.26M | 130.42M |
| Operating Income | -111.51M | -155.63M | -139.04M | -140.80M | -130.17M |
| Income Before Tax | -134.37M | -161.38M | -150.02M | -160.55M | -143.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -134.37M | -161.38M | -150.02M | -160.55M | -143.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.37M | -161.38M | -150.02M | -160.55M | -143.32M |
| EBIT | -111.51M | -155.63M | -139.04M | -140.80M | -130.17M |
| EBITDA | -109.22M | -153.33M | -136.66M | -138.39M | -127.77M |
| EPS Basic | -1.12 | -1.36 | -1.27 | -1.36 | -1.31 |
| Normalized Basic EPS | -0.70 | -0.85 | -0.79 | -0.85 | -0.82 |
| EPS Diluted | -1.12 | -1.36 | -1.27 | -1.36 | -1.31 |
| Normalized Diluted EPS | -0.70 | -0.85 | -0.79 | -0.85 | -0.82 |
| Average Basic Shares Outstanding | 119.46M | 118.50M | 118.08M | 117.69M | 109.24M |
| Average Diluted Shares Outstanding | 119.46M | 118.50M | 118.08M | 117.69M | 109.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |